nach oben

Current Psychiatry Reports

Erschienen in:

01.10.2014 | Mood Disorders (JF Greden, Section Editor)

Depression and Cardiovascular Disease: An Update on How Course of Illness May Influence Risk

verfasst von: Jess G. Fiedorowicz

Erschienen in: Current Psychiatry Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Depression constitutes a novel and independent risk factor for cardiovascular disease, which despite extensive support in the literature has been underappreciated. While much of the evidence for depression as a risk factor for cardiovascular disease is based on studies following myocardial infarction, the elevated vascular risk conveyed by depression is not confined to periods following acute coronary syndromes. For that matter, the risk appears across mood disorders with evidence for even greater risk in bipolar disorder. This review summarizes the literature linking depressive disorders to cardiovascular mortality with a focus on how the course of illness of mood disorders may influence this risk. Mood disorders may influence risk over decades of illness in a dose-response to symptom burden, or the persistence of affective symptomatology. This may be mediated through changes in the activity of the autonomic nervous system, the hypothalamic-pituitary-adrenal axis, and inflammatory cytokines. Whether treatment of depression can mitigate this risk is not established although there are suggestions to support this contention, which could be better studied with more effective treatments of depression and larger standardized samples. Directions for future study of mechanisms and treatment are discussed. Regardless of causal mechanisms, persons with depressive disorders and other risk factors for vascular disease represent a neglected, high-risk group for cardiovascular events. In addition to the appropriate treatment for depression, screening and optimized management of traditional risk factors for cardiovascular diseases is necessary.

Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the american heart association. Circulation. 2014;129(12):1350–69. doi:10.1161/CIR.0000000000000019.PubMedCrossRef

Wolff HG. Life stress and cardiovascular disorders. Circulation. 1950;1(2):187–203.PubMedCrossRef

Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584–636. doi:10.1161/CIR.0b013e3182051b4c.PubMedCrossRef

Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med. 2005;67 Suppl 1:S19–25. doi:10.1097/01.psy.0000162253.07959.db.PubMedCrossRef

Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68(6):899–907.PubMedCrossRef

Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–50.PubMedCrossRef

Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr Psychiatry Rep. 2009;11(6):475–80.PubMedCrossRef

Everson-Rose SA, House JS, Mero RP. Depressive symptoms and mortality risk in a national sample: confounding effects of health status. Psychosom Med. 2004;66(6):823–30. doi:10.1097/01.psy.0000145903.75432.1f.PubMedCrossRef

Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. J Psychosom Res. 2011;70(2):145–54. doi:10.1016/j.jpsychores.2010.07.010.PubMedCrossRefPubMedCentral

10.

Ormel J, Von Korff M, Burger H, Scott K, Demyttenaere K, Huang YQ, et al. Mental disorders among persons with heart disease - results from World Mental Health surveys. Gen Hosp Psychiatry. 2007;29(4):325–34. doi:10.1016/j.genhosppsych.2007.03.009.PubMedCrossRefPubMedCentral

11.

Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. B J Psychiatry: J Mental Sci. 2013;203:90–102. doi:10.1192/bjp.bp.112.111195.CrossRef

12.

Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105(9):1049–53.PubMedCrossRef

13.

Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry. 2011;33(3):203–16. doi:10.1016/j.genhosppsych.2011.02.007.PubMedCrossRef

14.

Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8(1):e55176. doi:10.1371/journal.pone.0055176.PubMedCrossRefPubMedCentral

15.

Fiedorowicz JG, Solomon DA, Endicott J, Leon AC, Li C, Rice JP, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71(6):598–606. doi:10.1097/PSY.0b013e3181acee26.PubMedCrossRefPubMedCentral

16.

Fiedorowicz JG. Jancic D. Butcher B, Coryell WH. Vascular Mortality in Participants of a Bipolar Genomics Study. Psychosomatics: Potash JB; 2014. doi:10.1016/j.psym.2014.02.001.

17.

Murray DP, Metz NS, Haynes WG, Fiedorowicz JG. Vascular function is not impaired early in the course of bipolar disorder. J Psychosom Res. 2012;72(3):195–8. doi:10.1016/j.jpsychores.2011.12.006.PubMedCrossRefPubMedCentral

18.

Sodhi SK, Linder J, Chenard CA, del Miller D, Haynes WG, Fiedorowicz JG. Evidence for accelerated vascular aging in bipolar disorder. J Psychosom Res. 2012;73(3):175–9. doi:10.1016/j.jpsychores.2012.06.004.PubMedCrossRefPubMedCentral

19.

Fiedorowicz JG, Coryell WH, Rice JP, Warren LL, Haynes WG. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom. 2012;81(4):235–43. doi:10.1159/000334779 000334779.PubMedCrossRefPubMedCentral

20.

Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. The American journal of cardiology. 2001;88(2):196-8, A7.

21.

Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88(5):521–3.PubMedCrossRefPubMedCentral

22.

Broadley AJ, Korszun A, Abdelaal E, Moskvina V, Deanfield J, Jones CJ, et al. Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol. 2006;48(1):170–5. doi:10.1016/j.jacc.2005.12.078.PubMedCrossRef

23.

Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60(8):889–91. doi:10.1016/j.biopsych.2006.03.025.PubMedCrossRef

24.

Wagner JA, Tennen H, Mansoor GA, Abbott G. History of major depressive disorder and endothelial function in postmenopausal women. Psychosom Med. 2006;68(1):80–6. doi:10.1097/01.psy.0000195868.68122.9e.PubMedCrossRef

25.

Wagner J, Tennen H, Mansoor G, Abbott G. Endothelial dysfunction and history of recurrent depression in postmenopausal women with Type 2 diabetes: a case-control study. J Diabetes Complicat. 2009;23(1):18–24. doi:10.1016/j.jdiacomp.2007.11.007.PubMedCrossRef

26.

Greenstein AS, Paranthaman R, Burns A, Jackson A, Malik RA, Baldwin RC, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. Hypertension. 2010;56(4):734–40. doi:10.1161/HYPERTENSIONAHA.110.152801.PubMedCrossRef

27.

Lavoie KL, Pelletier R, Arsenault A, Dupuis J, Bacon SL. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med. 2010;72(1):20–6. doi:10.1097/PSY.0b013e3181c2d6b8.PubMedCrossRef

28.

Oulis P, Kouzoupis A, Kyrkou K, Masdrakis VG, Georgiopoulos G, Karapoulios E, et al. Reversal of increased arterial stiffness in severely depressed women after 6-week antidepressant treatment. J Affect Disord. 2010;122(1–2):164–6. doi:10.1016/j.jad.2009.08.003.PubMedCrossRef

29.

Paranthaman R, Greenstein AS, Burns AS, Cruickshank JK, Heagerty AM, Jackson A, et al. Vascular function in older adults with depressive disorder. Biol Psychiatry. 2010;68(2):133–9. doi:10.1016/j.biopsych.2010.04.017.PubMedCrossRef

30.

Garcia RG, Zarruk JG, Barrera C, Pinzon A, Trillos E, Arenas WD, et al. Plasma nitrate levels and flow-mediated vasodilation in untreated major depression. Psychosom Med. 2011;73(4):344–9. doi:10.1097/PSY.0b013e31821566cf.PubMedCrossRef

31.

Seldenrijk A, van Hout HP, van Marwijk HW, de Groot E, Gort J, Rustemeijer C, et al. Depression, anxiety, and arterial stiffness. Biol Psychiatry. 2011;69(8):795–803. doi:10.1016/j.biopsych.2010.12.034.PubMedCrossRef

32.

Zhuo C, Wang Y, Tian H, Wang X, Chen Y, Mao F. Impairment of endothelial protection by ischemic postconditioning in patients with major depressive disorder. Can J Physiol Pharmacol. 2011;89(9):647–53. doi:10.1139/Y11-063.PubMedCrossRef

33.

Wagner JA, Tennen H, Finan PH, White WB, Burg MM, Ghuman N. Lifetime history of depression, type 2 diabetes, and endothelial reactivity to acute stress in postmenopausal women. Int J Behav Med. 2012;19(4):503–11. doi:10.1007/s12529-011-9190-5.PubMedCrossRef

34.

Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med. 2003;65(3):402–9.PubMedCrossRef

35.

Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005;46(4):656–9. doi:10.1016/j.jacc.2005.05.041.PubMedCrossRef

36.

Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29(9):1110–7. doi:10.1093/eurheartj/ehn137.PubMedCrossRef

37.

Cooper DC, Milic MS, Tafur JR, Mills PJ, Bardwell WA, Ziegler MG, et al. Adverse impact of mood on flow-mediated dilation. Psychosom Med. 2010;72(2):122–7. doi:10.1097/PSY.0b013e3181cdbfc0.PubMedCrossRefPubMedCentral

38.

Chen H, Zhang L, Zhang M, Song X, Zhang H, Liu Y, et al. Relationship of depression, stress and endothelial function in stable angina patients. Physiol Behav. 2013;118:152–8. doi:10.1016/j.physbeh.2013.05.024.PubMedCrossRef

39.

Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and impaired endothelial function in healthy adolescent women. J Behav Med. 2008;31(2):137–43. doi:10.1007/s10865-007-9141-4.PubMedCrossRef

40.

Tomfohr LM, Murphy ML, Miller GE, Puterman E. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med. 2011;73(6):456–61. doi:10.1097/PSY.0b013e3182228644.PubMedCrossRefPubMedCentral

41.

Osika W, Montgomery SM, Dangardt F, Wahrborg P, Gan LM, Tideman E, et al. Anger, depression and anxiety associated with endothelial function in childhood and adolescence. Arch Dis Child. 2011;96(1):38–43. doi:10.1136/adc.2008.152777.PubMedCrossRef

42.

Tiemeier H, Breteler MM, van Popele NM, Hofman A, Witteman JC. Late-life depression is associated with arterial stiffness: a population-based study. J Am Geriatr Soc. 2003;51(8):1105–10.PubMedCrossRef

43.

Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73(2):114–26. doi:10.1097/PSY.0b013e31820ad12b.PubMedCrossRef

44.

Belvederi Murri M, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46–62. doi:10.1016/j.psyneuen.2013.12.004.PubMedCrossRef

45.

Hatzinger M, Hemmeter UM, Baumann K, Brand S, Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J Psychiatr Res. 2002;36(5):287–97.PubMedCrossRef

46.

Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res. 1999;33(5):363–70.PubMedCrossRef

47.

Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67(11):1067–74. doi:10.1016/j.biopsych.2009.12.012.PubMedCrossRef

48.

Licht CM, Penninx BW, de Geus EJ. To include or not to include? A response to the meta-analysis of heart rate variability and depression. Biol Psychiatry. 2011;69(4):e1. doi:10.1016/j.biopsych.2010.06.034. author reply e3-4.PubMedCrossRef

49.

Baumert M, Lambert GW, Dawood T, Lambert EA, Esler MD, McGrane M, et al. Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2009;297(2):H674–9. doi:10.1152/ajpheart.00236.2009.PubMedCrossRef

50.

Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens. 2010;28(3):543–50. doi:10.1097/HJH.0b013e3283350ea4.PubMedCrossRef

51.

Scalco AZ, Rondon MU, Trombetta IC, Laterza MC, Azul JB, Pullenayegum EM, et al. Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. J Hypertens. 2009;27(12):2429–36. doi:10.1097/HJH.0b013e3283310ece.PubMedCrossRef

52.

Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25(10):2117–24. doi:10.1097/HJH.0b013e32829baae7.PubMedCrossRef

53.

Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51(5):411–22.PubMedCrossRef

54.

Baumert M, Lambert GW, Dawood T, Lambert EA, Esler MD, McGrane M, et al. QT interval variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2008;295(3):H962–H8. doi:10.1152/ajpheart.00301.2008.PubMedCrossRef

55.

Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487(7407):325–9. doi:10.1038/nature11260.PubMedCrossRefPubMedCentral

56.

Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.PubMed

57.

Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59(4):755–62. doi:10.1161/HYPERTENSIONAHA.111.186833.PubMedCrossRefPubMedCentral

58.

Straub RH, Buttgereit F, Cutolo M. Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S23–31.PubMed

59.

Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs healthy control subjects: a systematic review and meta-analysis. J Psychiatric Res. 2013;47(9):1119–33. doi:10.1016/j.jpsychires.2013.05.018.CrossRef

60.

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86. doi:10.1097/PSY.0b013e3181907c1b.PubMedCrossRef

61.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57. doi:10.1016/j.biopsych.2009.09.033.PubMedCrossRef

62.

Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64(2–3):185–93.PubMedCrossRef

63.

Su KP, Leu SJ, Yang YY, Shen WW, Chou YM, Tsai SY. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord. 2002;71(1–3):205–9.PubMedCrossRef

64.

O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2–3):263–7. doi:10.1016/j.jad.2005.11.015.PubMedCrossRef

65.

Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1–2):116–22. doi:10.1016/j.jneuroim.2004.01.006.PubMedCrossRef

66.

Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(4):952–5. doi:10.1016/j.pnpbp.2007.02.018.CrossRef

67.

Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602. doi:10.1111/j.1399-5618.2007.00493.x.PubMedCrossRef

68.

Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Goncalves CA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4. doi:10.1007/s00406-007-0797-0.PubMedCrossRef

69.

Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7. doi:10.1016/j.jad.2008.12.001.PubMedCrossRef

70.

Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608–16. doi:10.1016/j.jpsychires.2011.08.003.PubMedCrossRef

71.

Fontoura PC, Pinto VL, Matsuura C, Resende Ade C, de Bem GF, Ferraz MR, et al. Defective nitric oxide-cyclic guanosine monophosphate signaling in patients with bipolar disorder: a potential role for platelet dysfunction. Psychosom Med. 2012;74(8):873–7. doi:10.1097/PSY.0b013e3182689460.PubMedCrossRef

72.

Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6. doi:10.1016/j.jad.2011.08.022.PubMedCrossRef

73.

Barbosa IG, Morato IB, de Miranda AS, Bauer ME, Soares JC, Teixeira AL. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord. 2014;157:41–4. doi:10.1016/j.jad.2013.12.042.PubMedCrossRef

74.

De Berardis D, Conti CM, Campanella D, Carano A, Scali M, Valchera A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319–24.PubMed

75.

Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65(3):347–56.PubMedCrossRef

76.

Hiles SA, Baker AL, de Malmanche T, Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42(10):2015–26. doi:10.1017/S0033291712000128.PubMedCrossRef

77.

Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol: Off Publ Am College of Neuropsychopharmacol. 2011;36(12):2452–9. doi:10.1038/npp.2011.132.CrossRef

78.

Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.PubMedCrossRef

79.

Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol: Off Publ Am College Neuropsychopharmacol. 2000;22(4):370–9. doi:10.1016/S0893-133X(99)00134-7.CrossRef

80.

Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology. 2003;170(4):429–33. doi:10.1007/s00213-003-1566-z.PubMedCrossRef

81.

O'Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. B J Psychiatry: J Mental Sci. 2006;188:449–52. doi:10.1192/bjp.bp.105.011015.CrossRef

82.

Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, et al. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res: Off J Japanese Soc Hypertens. 2007;30(4):285–93. doi:10.1291/hypres.30.285.CrossRef

83.

Mackay GM, Forrest CM, Christofides J, Bridel MA, Mitchell S, Cowlard R, et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol. 2009;36(4):425–35. doi:10.1111/j.1440-1681.2008.05077.x.PubMedCrossRef

84.

Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86(5):527–32. doi:10.1038/clpt.2009.121.PubMedCrossRef

85.

Chen YC, Lin WW, Chen YJ, Mao WC, Hung YJ. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediat Inflamm. 2010;2010:573594. doi:10.1155/2010/573594.CrossRef

86.

Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA: J Am Med Assoc. 2010;303(1):47–53. doi:10.1001/jama.2009.1943.CrossRef

87.

Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA: J Am Med Assoc. 2002;288(6):701–9.CrossRef

88.

O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692–9. doi:10.1016/j.jacc.2010.03.068.PubMedCrossRefPubMedCentral

89.

Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA: J Am Med Assoc. 2003;289(23):3106–16. doi:10.1001/jama.289.23.3106.CrossRef

90.

Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606–13. doi:10.1097/PSY.0b013e31814b260d.PubMedCrossRef

91.

Santangelo A, Testai M, Barbagallo P, Crisafulli C, Grasso S, Manuele S, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline or Citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr. 2009;48(3):350–2. doi:10.1016/j.archger.2008.02.014.PubMedCrossRef

92.

Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600–8. doi:10.1001/archinternmed.2010.29.PubMedCrossRefPubMedCentral

93.

Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol. 2007;50(21):2044–50. doi:10.1016/j.jacc.2007.07.069.PubMedCrossRef

94.

Greden JF. The National Network of Depression Centers: progress through partnership. Depression Anxiety. 2011;28(8):615–21. doi:10.1002/da.20862.PubMedCrossRef

95.

Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322–30.PubMedCrossRef

96.

Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150(5):720–7.PubMed

97.

Merikangas KR, Ames M, Cui L, Stang PE, Ustun TB, Von Korff M, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64(10):1180–8.PubMedCrossRefPubMedCentral

98.

Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. doi:10.1371/journal.pmed.1001547.PubMedCrossRefPubMedCentral

Titel: Depression and Cardiovascular Disease: An Update on How Course of Illness May Influence Risk
verfasst von: Jess G. Fiedorowicz
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 10/2014
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-014-0492-6

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Behavioral Health Leadership: New Directions in Occupational Mental Health

Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments

Bereavement: Course, Consequences, and Care

Strategies for Successful Aging: A Research Update